Account
Publications
07.03.2024
World EPA Congress 2024: Implications of indicatio...

The study explores the complexities of pricing and reimbursement for multi-indication products in th...

Read more
News
13.02.2024
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more
Articles
08.02.2024
Is the attractiveness of launch in the UK changing...

This expert article focusses on the new proportionate approach, and the international recognition pr...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Are Acute Therapies And Curativ...

We've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Evaluation and Reimbursement of...

Our study compares and contrasts the evaluation and reimbursement pathways for digital therapeutics ...

Read more
Articles
07.09.2023
Prescription Price Puzzles: The Sky-High Cost of O...

This article explores the significant disparities between the US and Europe regarding orphan drugs a...

Read more
Insider Insights
29.08.2023
CMS announces first 10 drugs to undergo price nego...

The Centers for Medicare and Medicaid Services has unveiled a list of 10 drugs to undergo Medicare p...

Read more
News
02.08.2023
PMA Insights: Week 29

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
24.07.2023
Johnson & Johnson sue the US government

J&J sues US government, alleging infringement on First Amendment rights and unfair drug pricing unde...

Read more
Articles
09.06.2023
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.